PET/CT预测非小细胞肺癌表皮生长因子受体突变的研究进展

Advances on PET/CT in Predicting Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer

表皮生长因子受体(epidermal growth factor receptor,EGFR)突变在肺癌的启动及进展中至关重要,EGFR酪氨酸激酶抑制剂能阻断这一过程,实现了对肺癌的靶向治疗。目前,EGFR酪氨酸激酶抑制剂的应用要通过基因检测明确EGFR基因状态,而临床实践及基因检测方法存在一些问题,导致基因检测结果不易获得。正电子发射计算机断层显像(PET/CT)已广泛应用于肿瘤诊断及治疗等方面,近年研究显示氟[18F]标记的氟代脱氧葡萄糖代谢参数、新型分子探针及影像组学可协助临床在无法获得基因情况时检测EGFR基因状态及对突变类型进行分类,实现精准治疗。全文就近年来应用PET/CT预测非小细胞肺癌中EGFR突变的研究进展进行综述。

Epidermal growth factor receptor(EGFR)mutations are critical in the initiation and progression of lung cancer,and EGFR tyrosine kinase inhibitor(EGFR-TKI)can block this process,thus achieving targeted therapy for lung cancer.At present,the application of EGFR-TKI requires the identification of EGFR gene status through gene detection,but there are some problems of gene detection methods in clinical practice,resulting in the difficulty to obtain the accurate results.Positron emission tomography/computed tomography(PET/CT)has been widely used in the diagnosis and treatment of tumors,and recent studies have shown that the18 F-fluorodeoxyglucose(18 F-FDG)metabolic parameters can assist the detection of EGFR gene status and mutation types when EGFR gene status are not available clinically,so as to achieve precision therapy.In this review,the recent advances in the application of PET/CT to predict EGFR mutations in non-small cell lung cancer are reviewed.